AstraZeneca pays $68.5 million in Seroquel marketing case

Share this article:

Pharmaceutical giant AstraZeneca on Thursday agreed to pay $68.5 million to settle allegations that it inappropriately marketed the drug Seroquel for off-label uses, multiple states' authorities announced.

The settlement will be split among 37 states, making it the largest multi-state settlement from a pharmaceutical company in U.S. history, according to the Bureau of National Affairs. States had charged AstraZeneca with marketing the drug, which is approved to treat schizophrenia and bipolar disorder, for use on elderly patients with dementia, among others. In the lawsuit, states also claimed the company hid the nature of the drug's side effects from healthcare providers.

AstraZeneca has denied any wrongdoing. A company spokesman said that the settlement was paid in order to “bring these matters to a close and move forward with our business of providing medicines to patients.” Last year, the company paid the U.S. a $502 million settlement in a separate case involving the marketing of Seroquel.

Share this article:

More in News

Hospitals slap the government with lawsuits over 'two-midnight' policy to reduce observation stays

Hospitals slap the government with lawsuits over 'two-midnight' ...

The American Hospital Association and other hospital groups have sued the federal government over the so-called "two-midnight rule," which was designed in part to ease access to skilled nursing services. ...

Government would pay seniors to create advanced directives under Senate bill

Medicare beneficiaries would be paid to create advance directives and store them in an easy-access system if a recently proposed Senate bill were to become law.

MS patients less tense and pessimistic in nursing homes than at home, ...

Nursing home residents with severe multiple sclerosis report being less tense and pessimistic than similar individuals receiving care at home, according to recently published research findings.